Emergent BioSolutions Inc. (0IGA.L)
USD 4.17
(-6.36%)
USD 4.17
(-6.36%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 765.8 Million USD | 0.34% |
| 2022 | 763.2 Million USD | 188.11% |
| 2021 | 264.9 Million USD | 4.5% |
| 2020 | 253.5 Million USD | -60.61% |
| 2019 | 643.5 Million USD | -5.7% |
| 2018 | 682.4 Million USD | 513.99% |
| 2017 | -164.83 Million USD | -4721.15% |
| 2016 | -3.41 Million USD | 94.28% |
| 2015 | -59.79 Million USD | -102.7% |
| 2014 | -29.49 Million USD | 74.86% |
| 2013 | -117.33 Million USD | -48.73% |
| 2012 | -78.89 Million USD | 6.58% |
| 2011 | -84.44 Million USD | 30.55% |
| 2010 | -121.59 Million USD | -226.81% |
| 2009 | -37.2 Million USD | -8.5% |
| 2008 | -34.29 Million USD | 28.26% |
| 2007 | -47.79 Million USD | -42.05% |
| 2006 | -33.64 Million USD | -37.99% |
| 2005 | -24.38 Million USD | -503.31% |
| 2004 | 6.04 Million USD | 0.0% |
| 2002 | -4.89 Million USD | -117.5% |
| 2001 | 27.94 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 805.8 Million USD | -4.44% |
| 2024 Q1 | 843.2 Million USD | 10.11% |
| 2023 Q2 | 814.6 Million USD | -15.86% |
| 2023 Q4 | 765.8 Million USD | 135.05% |
| 2023 FY | 765.8 Million USD | 0.34% |
| 2023 Q1 | 968.2 Million USD | 26.86% |
| 2023 Q3 | 325.8 Million USD | -60.0% |
| 2022 FY | 763.2 Million USD | 188.11% |
| 2022 Q4 | 763.2 Million USD | -6.06% |
| 2022 Q2 | 467.1 Million USD | 17.57% |
| 2022 Q3 | 812.4 Million USD | 73.92% |
| 2022 Q1 | 397.3 Million USD | 49.98% |
| 2021 FY | 264.9 Million USD | 4.5% |
| 2021 Q1 | 311.3 Million USD | 22.8% |
| 2021 Q2 | 406.5 Million USD | 30.58% |
| 2021 Q3 | 445.1 Million USD | 9.5% |
| 2021 Q4 | 264.9 Million USD | -40.49% |
| 2020 Q1 | 607.7 Million USD | -5.56% |
| 2020 FY | 253.5 Million USD | -60.61% |
| 2020 Q4 | 253.5 Million USD | -45.41% |
| 2020 Q3 | 464.4 Million USD | -10.42% |
| 2020 Q2 | 518.4 Million USD | -14.69% |
| 2019 Q3 | 684.2 Million USD | 3.18% |
| 2019 Q4 | 643.5 Million USD | -5.95% |
| 2019 Q2 | 663.1 Million USD | 9.55% |
| 2019 FY | 643.5 Million USD | -5.7% |
| 2019 Q1 | 605.3 Million USD | -11.3% |
| 2018 Q2 | -176.75 Million USD | -17.73% |
| 2018 Q1 | -150.13 Million USD | 8.92% |
| 2018 FY | 682.4 Million USD | 513.99% |
| 2018 Q3 | -325.86 Million USD | -84.36% |
| 2018 Q4 | 682.4 Million USD | 309.41% |
| 2017 FY | -164.83 Million USD | -4721.15% |
| 2017 Q4 | -164.83 Million USD | -79.17% |
| 2017 Q3 | -91.99 Million USD | -37.44% |
| 2017 Q2 | -66.93 Million USD | -207.38% |
| 2017 Q1 | -21.77 Million USD | -536.91% |
| 2016 Q4 | -3.41 Million USD | 89.02% |
| 2016 FY | -3.41 Million USD | 94.28% |
| 2016 Q1 | -93.82 Million USD | -56.91% |
| 2016 Q2 | -86 Million USD | 8.34% |
| 2016 Q3 | -31.13 Million USD | 63.79% |
| 2015 Q3 | -55.71 Million USD | -246.02% |
| 2015 Q1 | 34.48 Million USD | 216.9% |
| 2015 Q4 | -59.79 Million USD | -7.32% |
| 2015 FY | -59.79 Million USD | -102.7% |
| 2015 Q2 | 38.15 Million USD | 10.65% |
| 2014 Q2 | 82.87 Million USD | -8.72% |
| 2014 Q1 | 90.78 Million USD | 177.37% |
| 2014 FY | -29.49 Million USD | 74.86% |
| 2014 Q4 | -29.49 Million USD | -437.09% |
| 2014 Q3 | 8.75 Million USD | -89.44% |
| 2013 Q4 | -117.33 Million USD | -3.71% |
| 2013 Q1 | -68.58 Million USD | 13.07% |
| 2013 Q2 | -95.7 Million USD | -39.55% |
| 2013 FY | -117.33 Million USD | -48.73% |
| 2013 Q3 | -113.13 Million USD | -18.22% |
| 2012 FY | -78.89 Million USD | 6.58% |
| 2012 Q3 | -134.88 Million USD | -35.37% |
| 2012 Q2 | -99.64 Million USD | -11.27% |
| 2012 Q1 | -89.55 Million USD | -6.05% |
| 2012 Q4 | -78.89 Million USD | 41.51% |
| 2011 FY | -84.44 Million USD | 30.55% |
| 2011 Q4 | -84.44 Million USD | -18.02% |
| 2011 Q3 | -71.55 Million USD | 13.57% |
| 2011 Q2 | -82.79 Million USD | 8.36% |
| 2011 Q1 | -90.34 Million USD | 25.7% |
| 2010 Q4 | -121.59 Million USD | -18.09% |
| 2010 Q1 | -51.42 Million USD | -38.21% |
| 2010 Q2 | -53.09 Million USD | -3.26% |
| 2010 Q3 | -102.96 Million USD | -93.92% |
| 2010 FY | -121.59 Million USD | -226.81% |
| 2009 FY | -37.2 Million USD | -8.5% |
| 2009 Q4 | -37.2 Million USD | 53.02% |
| 2009 Q3 | -79.19 Million USD | -68.67% |
| 2009 Q2 | -46.95 Million USD | -866.85% |
| 2009 Q1 | -4.85 Million USD | 85.84% |
| 2008 Q2 | -24.69 Million USD | 24.06% |
| 2008 Q4 | -34.29 Million USD | 25.94% |
| 2008 Q1 | -32.52 Million USD | 31.96% |
| 2008 FY | -34.29 Million USD | 28.26% |
| 2008 Q3 | -46.29 Million USD | -87.48% |
| 2007 Q3 | 22.7 Million USD | 1765.96% |
| 2007 Q2 | -1.36 Million USD | 96.02% |
| 2007 Q4 | -47.79 Million USD | -310.49% |
| 2007 Q1 | -34.26 Million USD | -1.82% |
| 2007 FY | -47.79 Million USD | -42.05% |
| 2006 Q4 | -33.64 Million USD | -303.1% |
| 2006 FY | -33.64 Million USD | -37.99% |
| 2006 Q3 | 16.56 Million USD | 0.0% |
| 2005 Q4 | -24.38 Million USD | 0.0% |
| 2005 FY | -24.38 Million USD | -503.31% |
| 2004 FY | 6.04 Million USD | 0.0% |
| 2004 Q4 | 6.04 Million USD | 0.0% |
| 2002 FY | -4.89 Million USD | -117.5% |
| 2001 Q4 | -544.5 Million USD | 0.0% |
| 2001 FY | 27.94 Million USD | 0.0% |
| 2000 Q4 | 314.7 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | 843.849% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 2553.151% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | -286.641% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -2301.756% |
| bluebird bio, Inc. | 108.57 Million USD | -605.345% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 8593.789% |
| Imunon, Inc. | -4.69 Million USD | 16396.138% |
| Editas Medicine, Inc. | -87.11 Million USD | 979.058% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 94.043% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 63.498% |
| Myriad Genetics, Inc. | 88.1 Million USD | -769.24% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | -331.923% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 2384.129% |
| Verastem, Inc. | -37.27 Million USD | 2154.295% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 90.701% |
| Waters Corporation | 1.96 Billion USD | 60.937% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 97.147% |
| Biogen Inc. | 6.28 Billion USD | 87.822% |
| Nektar Therapeutics | 210.24 Million USD | -264.25% |
| Perrigo Company plc | 3.32 Billion USD | 76.948% |
| Dynavax Technologies Corporation | 106.63 Million USD | -618.151% |
| Illumina, Inc. | 1.21 Billion USD | 36.919% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -10890.121% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 772.415% |
| Heron Therapeutics, Inc. | 145.07 Million USD | -427.861% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -10555.35% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | -102.192% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 10885.915% |
| Evolus, Inc. | 63.7 Million USD | -1102.047% |
| Adicet Bio, Inc. | -142 Million USD | 639.265% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 2180.752% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 2925.83% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | -66.95% |
| FibroGen, Inc. | 56.76 Million USD | -1249.023% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 33.118% |
| OPKO Health, Inc. | 230.68 Million USD | -231.971% |
| Homology Medicines, Inc. | 18.43 Million USD | -4053.604% |
| Geron Corporation | 14.76 Million USD | -5087.995% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 51.695% |
| Exelixis, Inc. | -73.05 Million USD | 1148.323% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 1511.457% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 607.072% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 787.42% |
| Zoetis Inc. | 4.76 Billion USD | 83.919% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 483.243% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 7704.012% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 108.007% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 5355.284% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 27.362% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 20.919% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 665.583% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 44.543% |
| Blueprint Medicines Corporation | 702.83 Million USD | -8.959% |
| Insmed Incorporated | 721.62 Million USD | -6.122% |
| TG Therapeutics, Inc. | 17.86 Million USD | -4187.314% |
| Incyte Corporation | -3.17 Billion USD | 124.119% |